30

# NUCLEAR MAGNETIC RESONANCE METHODS FOR IDENTIFYING SITES IN PAPILLOMAVIRUS E2 PROTEIN

This application claims the benefit of U.S. Provisional Application Serial Nos. 60/197,459, filed 17 April 2000, 60/211,055, filed 13 June 2000, and 60/268,444 filed 13 February 2001, which are incorporated herein by reference in their entireties.

## **BACKGROUND OF THE INVENTION**

An important aspect in understanding the function of biochemical processes is the elucidation of the nature of the associations between various species including, for example, the associations between ligands and proteins. Such associations may be non-covalent, wherein juxtapositions are energetically favored by hydrogen bonding, van der Waals forces, or electrostatic interactions, or they may be covalent. When physical binding is being studied, a target molecule is typically exposed to one or more compounds suspected of being ligands, and assays are then performed to determine if complexes between the target molecule and one or more of those compounds are formed. Such assays, as are well known in the art, test for gross changes (e.g., size, charge, and mobility) in the target molecule that indicate complex formation.

Where functional changes are measured, assay conditions are established that allow for measurement of biological or chemical events related to the target molecule (e.g., enzyme catalyzed reaction and receptor-mediated enzyme activation). To identify an alteration, the function of the target molecule is determined before and after exposure to the test compounds.

Assays involving the use of nuclear magnetic resonance (NMR) techniques are also known. NMR techniques may be used, for example, in conjunction with other assay methods to assess hits identified from physical binding screens or functional assay screens. If <sup>1</sup>H, <sup>13</sup>C, and/or <sup>15</sup>N resonance assignments are known for the target as well as either a solution or X-ray crystallographic structure, then the binding site location of identified ligands can be determined using NMR techniques.

10

15

20

25

As such, definitive resonance assignments of the target are required as a first step. A DNA-binding protein, E2, which is encoded by the papillomavirus and is involved in transcriptional regulation and viral replication, is one such target.

### SUMMARY OF THE INVENTION

In one aspect, the present invention provides a nuclear magnetic resonance method for identifying a site in a DNA-binding and dimerization domain of a papillomavirus E2 protein. In one embodiment, the method includes providing a first set of chemical shifts for atoms of a mixture including a ligand and the papillomavirus E2 protein, comparing the first set of chemical shifts to a second set of chemical shifts as listed in Table 1, and identifying at least a portion of the atoms that exhibit changes in chemical shifts, wherein the site includes the identified atoms. Preferably providing the first set of chemical shifts includes providing a mixture of the ligand and the papillomavirus E2 protein, allowing the ligand to interact with the papillomavirus E2 protein, obtaining a nuclear magnetic resonance spectrum of the mixture, and measuring chemical shifts of atoms from the spectrum. Preferably allowing the ligand to interact includes allowing the ligand and the protein to reach a binding equilibrium. Preferably the site is a ligand binding site. Preferably the papillomavirus E2 protein is encoded by the HPV-18 strain.

In another embodiment, the method includes providing a first  $^{1}H^{-15}N$  heteronuclear single quantum correlation spectrum of a mixture including a ligand and the papillomavirus E2 protein, comparing the first  $^{1}H^{-15}N$  heteronuclear single quantum correlation spectrum to a second  $^{1}H^{-15}N$  heteronuclear single quantum correlation spectrum as illustrated in Figure 2, and identifying at least a portion of the amino acids having atoms that exhibit changes in chemical shifts, wherein the site includes the identified amino acids. Preferably providing the first spectrum includes providing a mixture of the ligand and the papillomavirus E2 protein, allowing the ligand to interact with the papillomavirus E2 protein, and obtaining a  $^{1}H^{-15}N$  heteronuclear single quantum correlation spectrum of the mixture.

30 Preferably allowing the ligand to interact includes allowing the ligand and the

10

15

20

25

30

protein to reach a binding equilibrium. Preferably the site is a ligand binding site. Preferably the papillomavirus E2 protein is encoded by the HPV-18 strain.

In another aspect, the present invention provides a machine-readable data storage medium including a data storage material encoded with nuclear magnetic resonance chemical shifts as listed in Table 1, wherein when a first set of chemical shifts is provided, the chemical shifts encoded on the data storage material are capable of being read by the machine to create a second set of chemical shifts, and the machine having programmed instructions that are capable of causing the machine to compare the first and second sets of chemical shifts to arrive at structural information.

In another aspect, the present invention provides a computer-assisted method for identifying a ligand binding site in a DNA-binding and dimerization domain of a papillomavirus E2 protein. The method includes providing a first set of nuclear magnetic resonance chemical shifts for atoms of a mixture including the ligand and the papillomavirus E2 protein, causing the first set of chemical shifts to be entered into memory of a computer, causing the computer to read a second set of chemical shifts as listed in Table 1 from a machine-readable data storage medium, causing the computer to compare the first and second sets of chemical shifts, and causing the computer to identify at least a portion of the atoms that exhibit changes in chemical shifts, wherein the ligand binding site includes the identified atoms. Preferably the papillomavirus E2 protein is encoded by the HPV-18 strain. Preferably the method further includes causing the computer to visually display a spatial arrangement of atoms of the ligand binding site.

Methods disclosed in the present invention for identifying sites offer advantages over other methods known in the art. For example, the present invention preferably provides methods for efficiently identifying binding sites for a wide range of chemically and physically diverse potential ligands.

The term "binding" as used herein, refers to a condition of proximity between a chemical entity or compound, or portions thereof, and the target protein or portions thereof. The association may be non-covalent, wherein the juxtaposition

is energetically favored by hydrogen bonding, van der Waals forces, or electrostatic interactions, or it may be covalent. The association may be a static interaction, or an equilibrium may be reached between associated and non-associated species. Preferably, a ligand that binds to a ligand binding site in a DNA-binding and dimerization domain of a papillomavirus E2 protein would also be expected to bind to or interfere with another ligand binding site whose structure defines a shape that falls within an acceptable error.

The term "ligand" as used herein means any chemical entity, compound, or portion thereof, that is capable of binding to a protein.

The term "change in chemical shifts" as used herein means the observation of an increase or decrease in chemical shift for a resonance, an increase or decrease in intensity for a resonance, or the failure to observe a resonance when comparing a resonance of an atom from the spectrum of a mixture of ligand and protein to the resonance of the same atom from the spectrum of the protein without the ligand

15

20

10

5

# BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is an illustration of the deviations from random coil chemical shifts of  $^{13}$ C $_{\alpha}$  resonances (in parts per million (ppm)) with assignments for the DNA-binding and dimerization domain of papillomavirus (strain HPV-18) E2 protein as a function of residue number. Random coil chemical shift values are from Wishart et al., Biochem. Cell Biol., 76:153-63 (1998). Locations of secondary structure according to the X-ray structure of BPV-1, HPV-16 and HPV-31 are shown with  $\alpha$  ( $\alpha$ -helix) and  $\beta$  ( $\beta$ -sheet).

Figure 2 is an illustration of the 2-dimensional <sup>1</sup>H-<sup>15</sup>N heteronuclear single quantum correlation spectrum with assignments for the DNA-binding and dimerization domain of a 0.84 mM papillomavirus (strain HPV-18) E2 protein at 300°K.

30

### **DETAILED DESCRIPTION**

Papillomaviruses are a diverse group of small DNA viruses that infect epithelial cells and cause tumor formation. All of the papillomaviruses encode a DNA-binding protein, E2, that is involved in transcriptional regulation and viral replication. E2 protein consists of a C-terminal DNA-binding and dimerization domain (E2-DBD) and N-terminal transactivation domain, separated by a flexible region. E2-DBD from bovine papillomavirus-1 (BPV-1) has been extensively studied, and the X-ray crystallographic structure of E2-DBD bound to DNA consists of a homodimer that includes an eight-stranded β-barrel and two pairs of α-helices (Hedge et al., Nature, 359:505-12 (1992)). The solution and/or crystal structures of homologous E2-DBDs from human papillomavirus-31 (HPV-31) (Liang et al., Biochemistry, 35:2095-2103 (1996), Bussiere et al., Acta Cryst., D54:1367-76 (1998)) and HPV-16 (Hedge et al., J. Mol. Biol., 284:1479-89 (1998)) have been reported and are similar to BPV-1.

The present invention preferably relates to the E2-DBD from the high risk strain HPV-18. The E2 protein of HPV-18 represses the expression of the major viral transforming genes E6 and E7 and is a cofactor for the replication protein E1 binding to the origin (Kasukawa et al., <u>J. Virol.</u>, 72:8166-73 (1998)). The pivotal role of E2 in transcriptional regulation and viral replication makes it a potential target for antiviral therapy.

E2-DBD of HPV-18 has 55% and 60% sequence identity to HPV-16 and HPV-31, respectively, and binds to the ACCN<sub>6</sub>GGT recognition sequence. Preferably, two amino acid sequences are compared using the Blastp program, version 2.0.9, of the BLAST 2 search algorithm, as described by Tatusova et al., FEMS Microbiol Lett 174, 247-50 (1999), and available at http://www.ncbi.nlm.nih.gov/gorf/bl2.html. Preferably, the default values for all BLAST 2 search parameters are used, including matrix = BLOSUM62; open gap penalty = 11, extension gap penalty = 1, gap x\_dropoff = 50, expect = 10, wordsize = 3, and filter on. In the comparison of two amino acid sequences using the BLAST search algorithm, structural similarity is referred to as "identity."

10

15

20

25

The present invention provides a papillomavirus HPV-18 strain E2 protein DNA-binding domain having the <sup>1</sup>H-<sup>15</sup>N heteronuclear single quantum correlation spectrum shown in Figure 2. Each correlation is labeled as to the residue in the protein from which it arises if that has been determined. The process used to make the assignments is described in the examples. The chemical shifts of all assigned <sup>1</sup>H, <sup>13</sup>C, and <sup>15</sup>N resonances are listed in Table 1. The resonance assignments presented here provide the basis for determining sites, preferably binding site locations of ligands previously identified by other means. Chemical shift changes induced by addition of ligand to the protein sample are manifested by changes in the appearance of <sup>1</sup>H-<sup>15</sup>N HSQC spectra. Correlations that experience the largest ligand-induced chemical shift changes are preferably located near the ligand's binding site. To determine chemical shift changes, the protein <sup>1</sup>H, <sup>13</sup>C, and <sup>15</sup>N resonances are preferably assigned as extensively as possible.

Preferably, ligand binding sites include identified atoms that exhibit changes in chemical shifts. Preferably the identified atoms include at least one proton that, upon addition of ligand to the protein, either exhibits a change in <sup>1</sup>H chemical shift of at least about 0.04 ppm or is no longer observed. Preferably the identified atoms includes at least one carbon atom that, upon addition of ligand to the protein, either exhibits a change in <sup>13</sup>C chemical shift of at least about 0.2 ppm or is no longer observed. Preferably the identified atoms include at least one nitrogen atom that, upon addition of ligand to the protein, either exhibits a change in <sup>15</sup>N chemical shift of at least about 0.2 ppm or is no longer observed.

In order that this invention be more fully understood, the following examples are set forth. These examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention in any way.

### **EXAMPLES**

The HPV-18 E2 protein consists of 410 amino acids with the DBD residing at the C-terminus (amino acids #329-410). E2-DBD cloning procedures resulted in the addition of methionine before amino acid 329 and six histidine residues after

10

20

25

amino acid 410. Amino acid sequencing indicated that the N-terminal des-Met form of the E2-DBD protein was the major species produced.

E2-DBD was over-expressed in BL21 (DE3) *E. coli* cells using the pSRtac vector. Isotopically labeled samples were prepared in M9 glucose media containing <sup>15</sup>NH<sub>4</sub>Cl and unlabeled or U-<sup>13</sup>C-glucose. Cell pellets were lysed with intermittent mechanical disruption with a Tissuemizer (Tekmar Co., Cincinatti, OH). Clarified cell lysates were passed over Ni<sup>2+</sup>-NTA agarose (Qiagen, Inc., Valencia, CA), and further purified using Source 30Q anion exchange chromatography (Amersham Pharmacia Biotech, Inc.; Piscataway, NJ). The resulting E2-DBD exists as a homodimer of molecular weight 20.6 kDa under the conditions used for the NMR experiments.

The NMR samples typically consisted of 0.8 mM protein in buffer containing 20 mM phosphate, 50 mM NaCl, and 1 mM [<sup>2</sup>H<sub>10</sub>] dithiothreitol (DTT) at pH 6.5 in 90%  $^{1}H_{2}O/10\%$   $^{2}H_{2}O$  by volume. All NMR spectra were recorded at 27°C on a Bruker DRX-600 spectrometer (BRUKER NMR, Rheinstetten, Germany) using a 5 mm triple-resonance probe with 3-axis gradients. HNC $_{\alpha}$ , HN(CO)C $_{\alpha}$ ,  $C_{\beta}C_{\alpha}(CO)NH$ ,  $H_{\beta}H_{\alpha}(CO)NH$ , HNCO and HCCH-total correlation spectroscopy (HCCH-TOCSY) (mixing times 16 and 23 milliseconds) data sets were acquired using gradient-enhanced versions of the pulse sequences. Two-dimensional <sup>1</sup>H-<sup>15</sup>N Heteronuclear Single Quantum Correlation (HSQC) and <sup>15</sup>N edited Nuclear Overhauser Effect Spectroscopy-HSQC (NOESY-HSQC) (mixing time 80 milliseconds) spectra were also acquired. Proton chemical shifts were referenced to the  ${}^{1}H_{2}O$  signal at 4.70 parts per million (ppm) (tetramethylsilane (TMS) = 0 ppm). The <sup>15</sup>N and <sup>13</sup>C chemical shifts were referenced indirectly in a manner similar to that known in the art (e.g., Bax et al., J. Magn. Reson., 67:565-69 (1986)). Carrier frequencies were 4.70 ppm for <sup>1</sup>H, 118 ppm for <sup>15</sup>N, 54 ppm for <sup>13</sup>C<sub>a</sub>, 40 ppm for aliphatic <sup>13</sup>C, and 174 ppm for <sup>13</sup>C'. A combination of water flip-back (e.g., Grzesiek et al., J. Am. Chem. Soc., 115:12593-94 (1993)) and WATERGATE (e.g., Piotto et al., <u>J. Biomol. NMR</u>, 2:661-65 (1992)) techniques were used to eliminate

15

20

the water resonance. NMR data were processed using NMRPipe and NMRDraw software from Molecular Simulations, Inc. (San Diego, CA).

Sequence-specific backbone resonance assignments were accomplished using primarily 3-dimensional HNC $_{\alpha}$ , HN(CO)C $_{\alpha}$ , and C $_{\beta}$ C $_{\alpha}$ (CO)NH data sets. The  $^{13}$ C' and  $^{1}$ H $_{\alpha}$ ,  $^{1}$ H $_{\beta}$  chemical shifts were determined using HNCO and H $_{\beta}$ H $_{\alpha}$ (CO)NH data sets, respectively. The side chain  $^{1}$ H and  $^{13}$ C spin systems were assigned using the 3-dimensional HCCH-TOCSY experiments.

The assigned  $^{1}\text{H-}^{15}\text{N}$  HSQC spectrum of HPV-18 E2-DBD is shown in Figure 2. Chemical shift values for all  $^{1}\text{H}_{N}$ ,  $^{1}\text{H}_{\alpha}$ ,  $^{13}\text{C}_{\alpha}$ ,  $^{13}\text{C}_{\beta}$ ,  $^{13}\text{C}'$  and  $^{15}\text{N}_{\alpha}$  resonances except for the first four residues, the C-terminal five histidine residues, and Glu58 and Thr59 were assigned. Approximately 60% of the side chain  $^{1}\text{H}$  and  $^{13}\text{C}$  resonances were also assigned. Assigned  $^{1}\text{H}$ ,  $^{13}\text{C}$ , and  $^{15}\text{N}$  chemical shifts are listed in Table 1. The locations of secondary structure in the linear amino acid sequence predicted based on  $^{13}\text{C}_{\alpha}$  chemical shifts (see Wishart et al., J. Biomol. NMR, 4:171-80 (1994)) are shown in Figure 1 and are consistent with the crystal structures of BPV-1, HPV-16 and HPV-31.

The complete disclosure of all patents, patent applications, and publications, and electronically available material cited herein are incorporated by reference. The foregoing detailed description and examples have been given for clarity of understanding only. No unnecessary limitations are to be understood therefrom. The invention is not limited to the exact details shown and described, for variations obvious to one skilled in the art will be included within the invention defined by the claims.

Table 1:  ${}^{1}H$ ,  ${}^{13}C$ , and  ${}^{15}N$  chemical shifts of human papillomavirus E2-DBD. HA, HB, HG, HD, HE, CA, CB, CG, CD, CE refer to  $H_{\alpha}$ ,  $H_{\beta}$ ,  $H_{\gamma}$ ,  $H_{\delta}$ ,  $H_{\epsilon}$ ,  $C_{\alpha}$ ,  $C_{\beta}$ ,  $C_{\gamma}$ ,  $C_{\delta}$ , and  $C_{\epsilon}$  respectively.

5	#Atom		RES	ATOMS		ppm
	1	4	THR	HA	Н	5.01
	2	4	THR	HB	H	3.91
		4	THR	HG1	H	0.98
10	4	4	THR	HG2	H	0.98
10	5	4	THR	CA	C	59.95
	6 7	4 4	THR THR	CB CG2	C C	67.75 19.93
	8	5	THR	H	Н	9.18
	9	5	THR	C	C	171.68
15	10	5	THR	CA	C	57.48
13	11	5	THR	N	N	124.16
	12	6	PRO	HA	H	4.73
	13	6	PRO	CA	C	60.10
	14	6	PRO	CB	C	29.24
20	15	7	ILE	H	H	8.49
	16	7	ILE	HА	Н	5.85
	17	7	ILE	HВ	H	1.82
	18	7	ILE	HG2	Н	0.92
0.5	19	7	ILE	HD1	Н	0.49
25	20	7	ILE	C	C	173.65
	21	7	ILE	CA	C	57.29
	22 23	7 7	ILE	CB CG2	C C	42.10 16.79
	24	7	ILE ILE	CG2 CD1	C	12.90
30	25	7	ILE	N	N	115.39
50	26	8	ILE	Н	Н	8.90
	27	8	ILE	HA	Н	5.01
	28	8	ILE	HB	H	1.88
	29	8	ILE	HG2	Н	0.82
35	30	8	ILE	C	C	174.83
	31	8	ILE	CA	C	58.93
	32	8	ILE	CB	C	39.92
	33	8	ILE	CG2	С	15.73
10	34	8	ILE	N	N	115.93
40	35	9	HIS	H	H	8.91
	36	9 9	HIS	HA	H	5.68
	37 38	9	HIS HIS	HB2 HB3	H H	2.81 2.57
	39	9	HIS	С	C	173.19
45	40	9	HIS	CA	C	51.27
	41	9	HIS	CB	C	32.38
	42	9	HIS	N	N	119.91
	43	10	LEU	H	Н	8.98
	44	10	LEU	HA	Н	5.17
50	45	10	LEU	HB2	Н	1.66
	46	10	LEU	HB3	H	0.92
	47	10	LEU	HG	Н	1.47
	48	10	LEU	HD1	H	0.82
55	49	10	LEU	HD2	Н	0.71
55	50	10	LEU	C	C	172.40
	51 52	10	LEU	CA	C C	50.25 40.76
	52 53	10 10	LEU LEU	CB CG	C	23.68
	J <b>J</b>	10	ULU	ÇĞ	C	23.00

	54	10	LEU	N	N		122.16
	55	11	LYS	Н	H		8.76
	56 57	11 11	LYS LYS	HA HB2	H H		5.29 1.65
5	58	11	LYS	HB3	Н		1.44
	59	11	LYS	HG2	Н		1.40
	60	11	LYS	HG3	H		1.21
	61	11	LYS	HD2	Н		1.62
10	62 63	11 11	LYS LYS	HD3 HE2	H H		1.62 2.70
10	64	11	LYS	HE3	Н		2.70
	65	11	LYS	C	C		172.59
	66	11	LYS	CA	С		51.76
1.5	67	11	LYS	СВ	C		33.58
15	68 69	11 11	LYS	CG	C		22.68 27.38
	70	11	LYS LYS	CD CE	C		39.54
	71	11	LYS	N	N		120.73
	72	12	GLY	Н	Н		8.30
20	73	12	GLY	HA2	Н		4.43
	74 75	12 12	GLY	HA3	H		4.19
	75 76	12	${f GLY}$	C CA	C C		173.46 42.96
	77	12	GLY	N	N		109.97
25	78	13	ASP	Н	Н		8.50
	79	13	ASP	HA	Н		4.59
	80	13	ASP	HB2	Н		2.77
	81 82	13 13	ASP ASP	HB3 C	H C		2.61 168.61
30	83	13	ASP	CA	C		52.23
	84	13	ASP	CB	Ċ		40.03
	85	13	ASP	N	N		120.16
	86	14	ARG	H	H		8.61
35	87 88	14 14	ARG ARG	HA HB2	H H	-	3.58 1.72
33	89	14	ARG	HB3	H		1.68
	90	14	ARG	HG2	Н		1.47
	91	14	ARG	HG3	Н		1.47
40	92	14 14	ARG	HD2	Н		3.07
40	93 94	$\begin{array}{c} 14 \\ 14 \end{array}$	ARG ARG	HD3 C	H C		3.02 174.68
	95	14	ARG	CA	Č		58.64
	96	14	ARG	CB	С		27.87
4.5	97	14	ARG	CG	C		26.01
45	98 99	14	ARG	CD	C		40.85
	100	14 15	ARG ASN	N H	N H		122.34 8.64
	101	15	ASN	НA	Н		4.46
	102	15	ASN	HB2	Н		2.87
50	103	15	ASN	HB3	H		2.76
	104 105	15 15	ASN	C CA	C C		176.39 54.42
	106	15	ASN ASN	CB	C		35.59
	107	15	ASN	N	Ň		118.46
55	108	16	SER	Н	Н		8.35
	109	16	SER	HA	H		3.86
	110	16	SER	HB2	H		4.17
	111 112	16 16	SER SER	HB3 C	H C		3.63 175.96
60	113	16	SER	CA	Č		59.80
-	114	16	SER	CB	Č		59.96

	115 116	16 17	SER	N H	N H	118.74 8.10
	117	17	LEU LEU	HA	Н	3.84
5	118 119	17 17	LEU LEU	HB2 HB3	H H	1.64 1.17
,	120	17	LEU	HD1	H	0.45
	121	17	LEU	HD2	Н	0.38
	122 123	17 17	LEU LEU	C CA	C C	175.25 55.37
10	124	17	LEU	CB	С	38.75
	125 126	17 17	LEU LEU	CD1 CD2	C C	23.04 19.79
	127	17	LEU	N CDZ	N	121.15
1.5	128	18	LYS	Н	Н	7.83
15	129 130	18 18	LYS LYS	HA HB2	H H	3.91 1.97
	131	18	LYS	нвз	Н	1.97
	132	18	LYS LYS	HG2	H	1.39 1.27
20	133 134	18 18	LYS	HG3 HD2	H H	1.70
	135	18	LYS	HD3	H	1.60
	136 137	18 18	LYS LYS	HE2 HE3	H H	2.95 2.95
	138	18	LYS	C	C	175.74
25	139	18	LYS	CA	C	57.85
	140 141	18 18	LYS LYS	CB CD	C	29.95 27.55
	142	18	LYS	CE	C	39.77
30	143 144	18 19	LYS CYS	N H	N H	120.70 7.59
30	145	19	CYS	HA	H	4.20
	146	19	CYS	HB2	Н	3.02
	147 148	19 - 19	CYS CYS	HB3 C	H C	2.95 177.01
35	149	19	CYS	CA	C	60.14
	150 151	19 19	CYS CYS	CB N	C N	24.32 116.91
	152	20	LEU	Н	Н	8.03
40	153	20	LEU	HA	Н	4.09
40	154 155	20 20	LEU LEU	нв2 нв3	H H	1.80 1.54
	156	20	LEU	HD1	H	0.90
	157	20	LEU	HD2 C	H C	0.82 175.16
45	158 159	20 20	LEU LEU	CA	C	55.39
	160	20	LEU	СВ	C	39.82
	161 162	20 20	LEU LEU	CD1 CD2	C C	21.58 25.17
	163	20	LEU	N	N	121.40
50	164	21	ARG	H	Н	8.58
	165 166	21 21	ARG ARG	HA HB2	H H	3.61 1.95
	167	21	ARG	C	С	175.45
55	168 169	21 21	ARG ARG	CA CB	C C	58.16 27.32
))	170	21	ARG	N N	N	118.96
	171	22	TYR	H	H	7.43
	172 173	22 22	TYR TYR	HA C	H C	3.91 175.54
60	174	22	TYR	CA	С	59.04
	175	22	TYR	CB	С	35.58

	176	22	TYR	N	N		116.61
	177	23	ARG	Н	Н		7.88
	178	23	ARG	HA	Н		4.04
5	179 180	23 23	ARG ARG	НВ2 НВ3	H H		2.04
J	181	23	ARG	HG2	H		1.70
	182	23	ARG	HG3	Н		1.70
	183	23	ARG	HD2	Н		3.26
10	184	23	ARG	HD3	Н		3.26
10	185	23	ARG	C	C		176.67
	186 187	23 23	ARG ARG	CA CB	C		57.11 28.01
	188	23	ARG	CG	C		25.77
	189	23	ARG	CD	Ċ		41.55
15	190	23	ARG	N	N		119.89
	191	24	LEU	H	H		8.59
	192	24	LEU	HA	Н		4.18
	193	24	LEU	HB2	Н		1.89
20	194 195	24 24	LEU LEU	HB3 HD1	H H		1.46 0.80
20	196	24	LEU	HD2	Н		0.60
	197	24	LEU	C	C		177.05
	198	24	LEU	CA	С		55.00
	199	24	LEU	CB	С		38.81
25	200	24	LEU	CD1	C		21.32
	201	24	LEU	CD2	C		22.99
	202 203	24 25	LEU ARG	N H	N H		117.28 7.75
	204	25	ARG	HA	Н		4.26
30	205	25	ARG	HB2	Н		1.91
	206	25	ARG	HB3	Н		1.91
	207	25	ARG	HG2	Н		1.82
	208	25	ARG	HG3	H		1.82
35	209 210	25 25	ARG ARG	HD2 HD3	H H		3.11 3.11
55	211	25	ARG	C	C	•	177.46
	212	25	ARG	CA	Č		56.71
	213	25	ARG	СВ	С		27.46
40	214	25	ARG	CG	С		25.14
40	215	25	ARG	CD	C		41.30
	216 217	25 26	ARG LYS	N H	N H		120.30 7.28
	218	26	LYS	HA	Н		4.17
	219	26	LYS	HB2	H		1.60
45	220	26	LYS	нвз	Н		1.60
	221	26	LYS	HG2	H		1.22
	222	26	LYS	HG3	H		1.22
	223 224	26 26	LYS LYS	HD2 HD3	H H		1.57 1.57
50	225	26	LYS	HE2	H		2.86
	226	26	LYS	HE3	Н		2.88
	227	26	LYS	C	C		175.55
	228	26	LYS	CA	C		54.84
55	229	26	LYS	CB	C		29.70
55	230 231	26 26	LYS	CG CD	C C		22.19 26.73
	231	26 26	LYS LYS	CE	C		39.22
	233	26	LYS	N	N		115.77
	234	27	HIS	Н	Н		7.82
60	235	27	HIS	HA	H		5.01
	236	27	HIS	HB2	Н		3.40

	237 238	27 27	HIS HIS	HB3 C	H C	2.87 174.21
	239	27	HIS	CA	С	52.56
5	240	27	HIS	CB	C	27.78
5	241 242	27 28	HIS SER	N H	N H	118.14 7.50
	243	28	SER	HA	Н	3.46
	244	28	SER	HB2	Н	3.80
1.0	245	28	SER	HB3	Н	3.80
10	246	28	SER	C	C	173.31
	247 248	28 28	SER	CA CB	C C	58.63 60.65
	248	28	SER SER	N	N	114.42
	250	29	ASP	H	Н	8.46
15	251	29	ASP	HA	Н	4.42
	252	29	ASP	HB2	Н	2.43
	253	29	ASP	HB3	H	2.21
	25 <b>4</b> 255	29 29	ASP	C CA	C C	171.83 52.93
20	256	29 29	ASP ASP	CB	C	37.38
-0	257	29	ASP	N	N	118.29
	258	30	HIS	H	Н	8.31
	259	30	HIS	HA	H	4.90
25	260	30	HIS	HB2	H	3.75
25	261 262	30 30	HIS	HB3 C	H	3.33 175.04
	263	30	HIS HIS	CA	C C	53.95
	264	30	HIS	CB	Č	29.17
	265	30	HIS	N	N	116.46
30	266	31	TYR	H	Н	7.05
	267	31	TYR	HA	H	4.57
	268 269	31 31	TYR TYR	HB2 HB3	H H	2.58 2.58
	270	31	TYR	C	C	170.71
35	271	31	TYR	CA	Č	54.00
	272	31	TYR	CB	С	37.51
	273	31	TYR	N	N	112.10
	274 275	32	ARG	H	Н	8.78
40	276	32 32	ARG ARG	HA HB2	H H	4.24 1.90
10	277	32	ARG	HB3	H	1.90
	278	32	ARG	HG2	Н	0.50
	279	32	ARG	HG3	Н	0.50
15	280	32	ARG	HD2	H	2.44
45	281 282	32 32	ARG	HD3 C	H C	2.25 170.17
	283	32	ARG ARG	CA	C	55.16
	284	32	ARG	CB	C	27.64
	285	32	ARG	CG	C	28.32
50	286	32	ARG	CD	C	41.50
	287	32	ARG	N	N	119.90
	288 289	33 33	ASP ASP	H	H H	7.55 4.91
	290	33	ASP	HA HB2	Н	2.12
55	291	33	ASP	HB3	Н	1.75
	292	33	ASP	C	C	171.83
	293	33	ASP	CA	C	49.82
	294	33	ASP	СВ	C	42.75
60	295 296	33 34	ASP	Ŋ	N	118.71
vv	296 297	34 34	ILE ILE	H HA	H H	9.72 5.41
	,	<i>J</i> 1		*** 7	4.1	0.41

	298 299 300 301	34 34 34 34	ILE ILE ILE ILE	HB HG2 HD1 C	Н Н Н С	1.33 0.93 0.49 170	1 5 .37
5	302 303 304 305 306	34 34 34 34 35	ILE ILE ILE ILE SER	CA CB CG2 N H	С С N Н	57.3 39.6 17.2 116 9.53	64 26 .54
10	307 308 309 310 311	35 35 35 35 35	SER SER SER SER SER	HA HB2 HB3 C CA	н н н С	5.10 3.98 3.98 173 56.9	0 3 3 .41
15	312 313 314 315	35 35 36 36	SER SER SER SER	CB N H HA	C N H H	64.8 127. 8.34 4.1	81 .07 4 7
20	316 317 318 319 320 321	36 36 36 36 36 36	SER SER SER SER	HB2 HB3 C CA CB	H H C C	2.94 2.94 171 56.2 61.5	4 . 93 27 52
25	322 323 324 325 326	36 37 37 37 37 37	SER THR THR THR THR THR	N H HA HB HG2 C	N H H H C	8.8° 4.42 3.90 0.99	7 2 3 9
30	327 328 329 330 331	37 37 37 37 37 38	THR THR THR THR THR	CA CB CG2 N H	C C C N H	61.5 66.2 20.5 118 9.25	50 25 38 •94
35	332 333 334 335 336	38 38 38 38	TRP TRP TRP TRP	HA HB2 HB3 C	Н Н Н С	4.75 2.54 2.54 172	5 4 4 . 46
40	336 337 338 339 340 341	38 38 38 39 39	TRP TRP TRP HIS HIS	CA CB N H HA HB2	C N H H	52.3 29.5 129 7.89 4.4 2.43	53 .61 9
45	342 343 344 345 346	39 39 39 39 40	HIS HIS HIS HIS	HB3 C CA CB H	H C C C	2.43 169 52.0 30.3 8.56	3 .88 09 38
50	347 348 349 350 351	40 40 40 40 40	TRP TRP TRP TRP TRP	HA HB2 HB3 C CA	H H H C	5.08 3.64 2.87 171. 53.8	3 4 7 . 67
55	352 353 354 355 356	40 40 41 41 41	TRP TRP THR THR THR	CB N H HA HB	C N H H	27.7 120. 8.67 4.42 3.92	77 .03 7 2
60	357 358	41 41	THR THR	HG2 C	H C	0.99 175.	9

	359	41	THR	CA	С	62.27
	360	41	THR	CB	C	67.99
	361	41	THR	CG2	C	20.38
5	362	41	THR	N	N	115.31
3	363 364	42 42	${ t GLY}$	H HA2	H H	9.77 4.03
	365	42	GLY	HA3	H H	4.03
	366	42	GLY	C	C	173.88
	367	42	GLY	CA	C	43.28
10	368	42	GLY	N	N	114.16
	369	43	ALA	Н	Н	8.31
	370	43	ALA	HA	H	4.32
	371	43	ALA	HB	H	1.39
	372	43	ALA	С	С	172.26
15	373	43	ALA	CA	С	50.72
	374	43	ALA	CB	С	16.84
	375	43	ALA	N	N	123.70
	376	44	$\operatorname{GLY}$	Н	Н	8.42
20	377	44	GLY	HA2	Н	4.10
20	378	44	GLY	EAH	H	3.91
	379	44	GLY	C	C	176.29
	380 381	44	GLY	CA	C	43.25
	382	44 45	GLY ASN	N	N	108.16 4.75
25	383	45	ASN	HA HB2	H H	2.93
23	384	45	ASN	HB3	Н	2.75
	385	45	ASN	C	C	172.12
	386	45	ASN	CA	Č	50.98
	387	45	ASN	CB	C	37.51
30	388	45	ASN	N	N	117.19
	389	46	GLU	Н	Н	8.81
	390	46	GLU	HA	H	3.98
	391	46	GLU	HB2	H	1.93
2.5	392	46	$\operatorname{GLU}$	нвз	Н	1.87
35	393	46	GLU	HG2	Н	2.14
	394	46	GLU	HG3	H	2.14
	395	46	GLU	C	C	173.36
	396 397	46 46	GLU	CA	C	55.97
40	398	46	GLU GLU	CB CG	C C	27.17 33.95
10	399	46	GLU	И	N	119.81
	400	47	LYS	Н	Н	8.17
	401	47	LYS	HA	Н	4.19
	402	47	LYS	нв2	Н	1.94
45	403	47	LYS	нвз	Н	1.76
	404	47	LYS	HG2	H	1.40
	405	47	LYS	HG3	Н	1.33
	406	47	LYS	HD2	Н	1.60
60	407	47	LYS	HD3	H	1.60
50	408	47	LYS	HE2	Н	2.94
	409	47	LYS	HE3	H	2.94
	410	47	LYS	C	C	174.43
	411 412	47 47	LYS	CA CB	C	54.79
55	412	47	LYS		C	30.57
55	413	47	LYS LYS	CG CD	C C	22.93 26.73
	415	47	LYS	CE	C	39.80
	416	47	LYS	N	N	117.28
	417	48	THR	Н	Н	7.49
60	418	48	THR	нA	Н	4.37
	419	48	THR	HB	Н	3.99

5	420 421 422 423	48 48 48	THR THR THR THR	HG1 HG2 C CA	H H C	1.05 1.05 174.80 59.28
J	424 425 426 427	48 48 48	THR THR THR GLY	CB CG2 N H	C C N H	68.23 19.72 113.55 8.64
10	428 429 430 431 432	49 49 49 49	GLY GLY GLY GLY	HA2 HA3 C CA N	H H C C N	4.28 3.05 171.67 42.01 111.32
15	433 434 435 436 437	50 50 50 50 50	ILE ILE ILE ILE	H HA HB HG2 C	Н Н Н Н С	8.29 4.53 -1.31 -0.31 168.12
20	438 439 440 441 442	50 50 50 51 51	ILE ILE ILE LEU LEU	CA CB N H HA	С С <b>N</b> Н	57.68 37.82 119.88 8.39 4.30
25	443 444 445 446 447	51 51 51 51 51	LEU LEU LEU LEU	HB2 HB3 HG HD1 C	Н Н Н Н	1.44 1.24 1.44 0.67 171.45
30	448 449 450 451 452	51 51 51 51 51	LEU LEU LEU LEU	CA CB CG CD1 N	С С С С	51.06 44.03 24.41 23.46 120.99
35	453 454 455 456 457	52 52 52 52 52	THR THR THR THR THR	H HA HB HG2 C	Н Н Н Н С	. 8.89 5.22 3.52 1.30 173.14
40	458 459 460 461 462	52 52 52 52 53	THR THR THR THR VAL	CA CB CG2 N H	С С И Н	59.30 72.25 22.71 120.58 8.97
45	463 464 465 466 467	53 53 53 53	VAL VAL VAL VAL VAL	HA HB HG1 HG2 C	Н Н Н С	4.71 1.65 0.43 0.16 170.60
50	468 469 470 471 472	53 53 53 53	VAL VAL VAL VAL	CA CB CG1 CG2 N	C C N	58.06 31.00 18.20 20.37 127.66
55	473 474 475 476 477	54 54 54 54	THR THR THR THR THR	H HA HB HG2 C	H H H C	8.63 5.00 3.87 1.03 172.93
60	478 479 480	54 54 54	THR THR THR	CA CB CG2	C C	56.41 68.61 19.60

	481	54	THR	N	N	114.36
	482	55	TYR	H	Н	7.26 4.61
	483 484	55 55	TYR TYR	HA HB2	H H	3.55
5	485	55	TYR	HB3	Н	3.55
	486	55	TYR	С	С	171.06
	487	55	TYR	CA	C	55.21
	488	55	TYR	CB	C	40.88 113.74
10	489 490	55 56	TYR HIS	N H	N H	9.34
10	491	56	HIS	HA.	Н	4.42
	492	56	HIS	нв2	Н	3.08
	493	56	HIS	нв3	Н	2.81
	494	56	HIS	C	C	173.18
15	495	56	HIS	CA	C	56.49
	496 497	56 56	HIS HIS	CB N	C N	29.81 118.21
	497	57	SER	H	Н	7.34
	499	57	SER	C	C	173.49
20	500	57	SER	CA	С	54.41
	501	57	SER	N	N	105.78
	502	59	THR	AH	H	3.91
	503 504	59 59	THR THR	HB HG2	H H	4.07 1.20
25	505	59	THR	CA	C	64.19
20	506	59	THR	CB	C	66.34
	507	59	THR	CG2	С	18.99
	508	60	GLN	H	H	8.02
20	509	60	GLN	AH	H	4.06
30	510 511	60 60	GLN GLN	HB2 HB3	H H	2.09 2.09
	512	60	GLN	HG2	H	3.26
	513	60 .	GLN	HG3	H	3.26
	514	60	GLN	С	С	174.20
35	515	60	GLN	CA	C	56.90
	516	60	GLN	CB	C	27.27
	517 518	60 60	GLN GLN	CG N	C N	41.55 123.81
	519	61	ARG	H	Н	7.31
40	520	61	ARG	HA	Н	2.99
	521	61	ARG	HB2	Н	1.70
	522	61	ARG	нвз	H	1.70
	523	61	ARG	C	C	175.22 57.25
45	524 525	61 61	ARG ARG	CA CB	C	27.77
15	526	61	ARG	N	Ň	119.25
	527	62	THR	H	Н	8.47
	528	62	THR	HA	Н	3.71
50	529	62	THR	HB	H	4.21
50	530 531	62 62	THR THR	HG2 C	H C	1.16 174.94
	532	62	THR	CA	C	64.67
	533	62	THR	CB	Ċ	66.46
	534	62	THR	CG2	С	19.65
55	535	62	THR	N	N	117.57
	536	63	LYS	H	H	7.88
	537 538	63 63	LYS LYS	HA HB2	H H	4.05 1.90
	539	63	LYS	HB3	Н	1.90
60	540	63	LYS	HG2	H	1.29
	541	63	LYS	HG3	Н	1.29

	542	63	LYS	HD2	Н	1.59
	543	63	LYS	HD3	Н	1.59
	544	63	LYS	HE2	Н	2.84
_	545	63	LYS	HE3	Н	2.79
5	546	63	LYS	C	C	173.47
	547	63	LYS	CA	C	57.28 29.34
	548 549	63 63	LYS LYS	CB CG	C C	22.63
	550	63	LYS	CD	Ċ	26.76
10	551	63	LYS	CE	Č	39.80
10	552	63	LYS	N	N	121.56
	553	64	PHE	нА	Н	3.94
	554	64	PHE	HB2	Н	3.75
	555	64	PHE	нвз	Н	3.75
15	556	64	PHE	C	С	177.53
	557	64	PHE	CA	С	59.77
	558	64	PHE	CB	С	35.86
	559	64	PHE	N	N	122.19
20	560	65	LEU	H	H	8.46
20	561	65	LEU	HA	H	4.03
	562	65 65	LEU	HB2	Н	1.92 1.33
	563 564	65 65	LEU	HB3 HD1	H H	0.67
	565	65 65	LEU LEU	HD2	H	0.48
25	566	65	LEU	C C	C	174.91
23	567	65	LEU	CA	Č	54.86
	568	65	LEU	СВ	Č	39.32
	569	65	LEU	CD1	C	19.30
	570	65	LEU	CD2	С	22.91
30	571	65	LEU	N	N	118.84
	572	66	ASN	H	Н	7.89
	573	66	ASN	HА	Н	4.72
	574	66	ASN	HB2	Н	2.84
25	575	66	ASN	нвз	H	2.76
35	576	66	ASN	C	С	. 176.34
	577 578	66	ASN	CA CB	C C	51.67 37.26
	579	66 66	ASN ASN	N	N	114.93
	580	67	THR	Н	Н	7.52
40	581	67	THR	нA	H	4.25
	582	67	THR	НВ	Н	3.74
	583	67	THR	HG2	H	0.96
	584	67	THR	С	C	173.66
	585	67	THR	CA	C	61.85
45	586	67	THR	CB	С	68.91
	587	67	THR	CG2	С	18.92
	588	67	THR	И	N	112.40
	589	68	VAL	H	H	7.73
50	590 591	68 68	VAL	HA	H H	3.39 1.05
50	592	68 68	VAL VAL	HB HG1	Н	0.16
	593	68	VAL	HG2	H	-0.12
	594	68	VAL	C	C	171.61
	595	68	VAL	CA	Ċ	60.07
55	596	68	VAL	СВ	C	29.25
	597	68	VAL	CG1	С	18.45
	598	68	VAL	CG2	С	17.60
	599	68	VAL	N	N	122.00
<i>(</i> 0	600	69	ALA	H	Н	8.12
60	601	69	ALA	AH	H	4.23
	602	69	ALA	HB	Н	1.19

604 69 ALA CA C 49.53 605 69 ALA CB C 15.99 606 69 ALA N N 129.1 5 607 70 ILE H H 8.40 608 70 ILE C C 174.0 609 70 ILE CA C 54.26 610 70 ILE N N 125.8 611 71 PRO HA H 4.43 10 612 71 PRO HB3 H 1.92 613 71 PRO HG2 H 3.83 614 71 PRO HG3 H 3.35 615 71 PRO CA C 60.85 616 71 PRO CB C 30.38	) . 7 . 7 . 9 . 5 . 9 . 5 . 7
5 606 69 ALA N N 129.1 607 70 ILE H H 8.40 608 70 ILE C C 174.0 609 70 ILE CA C 54.26 610 70 ILE N N 125.8 611 71 PRO HA H 4.43 10 612 71 PRO HB3 H 1.92 613 71 PRO HG2 H 3.83 614 71 PRO HG3 H 3.35 615 71 PRO CA C 60.85 616 71 PRO CB C 30.38	.7 .7 .6 .6 .6 .7 .7
5       607       70       ILE       H       H       8.40         608       70       ILE       C       C       174.0         609       70       ILE       CA       C       54.26         610       70       ILE       N       N       125.8         611       71       PRO       HA       H       4.43         10       612       71       PRO       HB3       H       1.92         613       71       PRO       HG2       H       3.83         614       71       PRO       HG3       H       3.35         615       71       PRO       CA       C       60.85         616       71       PRO       CB       C       30.38	)4 5 9 5 1 5 7
609 70 ILE CA C 54.26 610 70 ILE N N 125.8 611 71 PRO HA H 4.43 10 612 71 PRO HB3 H 1.92 613 71 PRO HG2 H 3.83 614 71 PRO HG3 H 3.35 615 71 PRO CA C 60.85 616 71 PRO CB C 30.38	5 19 5 5 7
610 70 ILE N N 125.8 611 71 PRO HA H 4.43 10 612 71 PRO HB3 H 1.92 613 71 PRO HG2 H 3.83 614 71 PRO HG3 H 3.35 615 71 PRO CA C 60.85 616 71 PRO CB C 30.38	55 55 57
10 611 71 PRO HA H 4.43 10 612 71 PRO HB3 H 1.92 613 71 PRO HG2 H 3.83 614 71 PRO HG3 H 3.35 615 71 PRO CA C 60.85 616 71 PRO CB C 30.38	51 51
10       612       71       PRO       HB3       H       1.92         613       71       PRO       HG2       H       3.83         614       71       PRO       HG3       H       3.35         615       71       PRO       CA       C       60.85         616       71       PRO       CB       C       30.38	51
613 71 PRO HG2 H 3.83 614 71 PRO HG3 H 3.35 615 71 PRO CA C 60.85 616 71 PRO CB C 30.38	51
614 71 PRO HG3 H 3.35 615 71 PRO CA C 60.85 616 71 PRO CB C 30.38	51
615 71 PRO CA C 60.85 616 71 PRO CB C 30.38	51
	3 51 5
	51
15 617 71 PRO CG C 25.23	; )
618 72 ASP H H 8.56	; )
619 72 ASP HA H 4.19 620 72 ASP HB2 H 2.65	; )
621 72 ASP HB3 H 2.65	; )
20 622 72 ASP C C 174.6	; )
623 72 ASP CA C 53.85	
624 72 ASP CB C 38.07	)3
625 72 ASP N N 120.0	
626 73 SER H H 7.48	
25 627 73 SER HA H 4.26 628 73 SER HB2 H 4.07	
628 73 SER HB2 H 4.07 629 73 SER HB3 H 3.83	
630 73 SER C C 173.9	8
631 73 SER CA C 55.90	
<b>30</b> 632 73 SER CB C 60.58	
633 73 SER N N 109.6	9
634 74 VAL H H 7.83	
635 74 VAL HA H 4.45 636 74 VAL HB H 1.99	
35 637 74 VAL HG1 H 0.66	
638 74 VAL HG2 H 0.62	
639 74 VAL C C 171.9	2
640 74 VAL CA C 59.08	
641 74 VAL CB C 30.98	
40 642 74 VAL CG1 C 20.02 643 74 VAL CG2 C 20.02	
643 74 VAL CG2 C 20.02 644 74 VAL N N 125.4	
645 75 GLN H H 8.94	_
646 75 GLN HA H 4.45	
<b>45</b> 647 75 GLN HB2 H 2.03	
648 75 GLN HB3 H 1.90	
649 75 GLN HG2 H 2.43	
650 75 GLN HG3 H 2.23 651 75 GLN C C 172.0	
651 75 GLN C C 172.0 50 652 75 GLN CA C 53.00	
653 75 GLN CB C 28.74	
654 75 GLN CG C 32.19	
655 75 GLN N N 125.6	5
656 76 ILE H H 8.83	
55 657 76 ILE HA H 4.63	
658 76 ILE HB H 1.88	
659 76 ILE HG2 H 0.67 660 76 ILE C C 172.7	6
661 76 ILE CA C 58.71	
60 662 76 ILE CB C 37.76	
663 76 ILE CG2 C 15.81	

	664	76	ILE	N	N	122.43
	665	77 77	LEU	H HA	H H	9.07 5.04
	666 667	77	LEU LEU	пА HB2	H	1.65
5	668	77	LEU	HB3	H	1.30
•	669	77	LEU	HG	Н	1.43
	670	77	LEU	HD1	Н	0.74
	671	77	LEU	HD2	Н	0.60
	672	77	LEU	С	С	172.98
10	673	77	LEU	CA	С	51.54
	674	77	LEU	CB	С	41.98
	675	77	LEU	CG	C	25.94
	676	77	LEU	CD1	C	22.69
1.5	677	77	LEU	CD2	C	22.12
15	678	77	LEU	N	N	128.16
	679 680	78 78	VAL	H HA	H H	8.87 4.38
	681	78	VAL VAL	HB	H	1.55
	682	78	VAL	HG1	Н	0.71
20	683	78	VAL	HG2	Н	0.71
	684	78	VAL	C	C	173.14
	685	78	VAL	CA	С	58.45
	686	78	VAL	CB	С	32.33
	687	78	VAL	CG1	С	19.09
25	688	78	VAL	CG2	C	19.09
	689	78	VAL	N	N	121.05
	690	79	GLY	H	Н	7.86
	691	79	GLY	HA2	H	5.08
30	692	79 70	GLY	HA3	H	4.08 172.86
30	693 694	79 79	GLY GLY	C CA	C C	44.62
	695	79 79	GLY	N	N	111.73
	696	80	TYR	Н	Н	8.54
	697	80	TYR	HA	Н	5.37
35	698	80	TYR	HB2	Н	2.99
	699	80	TYR	HB3	H	2.61
	700	80	TYR	С	C	169.75
	701	80	TYR	CA	C	54.23
40	702	80	TYR	СВ	С	40.30
40	703	80	TYR	N	N	119.24
	704	81	MET	H	H	8.60
	705	81	MET	HA	Н	5.35 1.94
	706 707	81 81	MET MET	HB2 HB3	H H	1.94
45	708	81	MET	HG2	Н	2.55
	709	81	MET	HG3	Н	2.50
	710	81	MET	C	C	171.31
	711	81	MET	CA	C	51.86
	712	81	MET	CB	C	34.66
50	713	81	MET	CG	С	29.09
	714	81	MET	N	N	117.15
	715	82	THR	Н	H	8.53
	716	82	THR	HA	H	4.98
55	717	82	THR	HB	H	3.51
55	718	82	THR	HG2	H	1.06
	719 720	82 82	THR	C CA	C C	172.03 59.38
	721	82	THR THR	CB	C	68.52
	722	82	THR	CG2	C	19.60
60	723	82	THR	N	N	122.12
-	724	83	MET	Н	Н	8.25

	725	83	MET	HA	Н	5.19
	726	83	MET	С	С	170.95
	727	83	MET	CA	С	51.06
	728	83	MET	CB	С	33.27
5	729	83	MET	N	N	122.01
-	730	84	HIS	H	H	8.90
	731	84	HIS	С	С	173.02
	732	84	HIS	CA	С	53.04
	733	84	HIS	N	N	118.65
10						